Advanced Sleep Phase Syndrome: Disease Characteristics Report

Executive summary

Advanced sleep phase syndrome (ASPS) is the older name for advanced sleep–wake phase disorder (ASWPD), an intrinsic circadian rhythm sleep–wake disorder in which the principal sleep episode is stably advanced—usually by at least 2 hours—relative to desired or socially required times. Typical sleep occurs around 18:00–21:00, with awakening around 02:00–05:00. A diagnosis requires distress or functional impairment; an extreme “morning lark” who functions well is an advanced chronotype, not necessarily affected by ASWPD. Familial advanced sleep phase (FASP/FASPS) denotes the inherited phenotype and is usually autosomal dominant. (sun2022treatmentofcircadian pages 5-6, ashbrook2020geneticsofthe pages 4-5, auger2015clinicalpracticeguideline pages 9-10)

The best-established biology involves the core circadian transcription–translation feedback loop (TTFL). Rare variants affecting PER2, CSNK1D, CRY2, PER3, and TIMELESS can alter clock-protein phosphorylation, stability, nuclear localization, intrinsic period, or light entrainment. However, only a small number of families have been studied, penetrance can be incomplete, and environmental light schedules can mask or amplify the phenotype. (lane2023geneticsofcircadian pages 6-7, kurien2019timelessmutationalters pages 1-2)

The principal evidence-based treatment is correctly timed evening bright-light therapy, but the American Academy of Sleep Medicine (AASM) recommendation is only WEAK FOR, based on very-low-quality evidence. No disease-modifying drug, gene therapy, or approved genotype-specific treatment exists. (auger2015clinicalpracticeguideline pages 9-10)

1. Disease information

Definition and identifiers

• Preferred clinical name: advanced sleep–wake phase disorder (ASWPD).
• Synonyms: advanced sleep phase syndrome/disorder (ASPS/ASPD), familial advanced sleep phase syndrome (FASPS), familial advanced sleep phase (FASP), advanced sleep phase type circadian rhythm sleep disorder.
• MONDO: MONDO:0015609, “advanced sleep phase syndrome.” Open Targets recognizes this entity but returned no curated disease–target associations, illustrating that absence from an aggregation platform does not negate the primary genetic literature. (OpenTargets Search: advanced sleep phase syndrome)
• MeSH: the broader concept D020178, Sleep Disorders, Circadian Rhythm is used in ClinicalTrials.gov indexing. (NCT00246454 chunk 1)
• ICD-10-CM: commonly coded G47.22, circadian rhythm sleep disorder, advanced sleep phase type. This code was not independently verified in the retrieved primary literature and should be checked against the deployment jurisdiction.
• ICD-11: classified under circadian rhythm sleep–wake disorders; the exact local extension/code should be verified against the current ICD-11 browser.
• OMIM: familial forms are represented as genetically heterogeneous FASPS entries; because exact OMIM disease-number mapping was not directly retrieved, OMIM numbers should not be populated without database verification.
• Orphanet: no independently verified dedicated Orphanet identifier was recovered.

This report primarily uses aggregated disease-level resources, guidelines, primary family studies, and observational cohorts, not individual EHR data. Family reports necessarily contain individual-level phenotyping, but the ClinicalTrials.gov records provide aggregated protocol information. (NCT00246454 chunk 1, NCT04690504 chunk 1)

Key source quotation

The landmark PER2 report describes FASPS as “an autosomal dominant circadian rhythm variant; affected individuals are ‘morning larks’ with a 4-hour advance of the sleep, temperature, and melatonin rhythms.” Science, February 2001; DOI: 10.1126/science.1057499; PMID 11232563. (toh2001anhper2 pages 1-2)

2. Etiology

Causal factors

ASWPD is etiologically heterogeneous:

1. Rare Mendelian disease: typically autosomal-dominant FASP caused by variants in core clock or clock-regulatory genes.
2. Non-Mendelian advanced chronotype: an extreme of polygenic sleep-timing variation.
3. Age-associated phase advance: earlier circadian timing becomes more common with aging and does not always constitute a disorder.
4. Environmental/behavioral reinforcement: morning light, insufficient evening light, rigid early schedules, and reduced evening activity can stabilize an advanced phase. (sun2022treatmentofcircadian pages 5-6, ashbrook2020geneticsofthe pages 4-5, lane2023geneticsofcircadian pages 6-7)

Risk factors

• Genetic: pathogenic or candidate variants in PER2, CSNK1D, CRY2, PER3, and TIMELESS. A 2023 authoritative review also lists CRY1 among rare variants implicated across advanced or delayed SWPD, but CRY1 is better established for delayed phase and should not automatically be annotated as an ASWPD-causal gene. (lane2023geneticsofcircadian pages 6-7)
• Family history: strongly increases suspicion of FASP, especially when multiple generations show very early sleep and wake times.
• Age: advanced sleep timing becomes increasingly common with age; this is a risk for the phenotype but not proof of Mendelian disease. (ashbrook2020geneticsofthe pages 4-5)
• Sex: one review reports higher prevalence in men, but robust population estimates are lacking. (sun2022treatmentofcircadian pages 5-6)
• Light environment: disproportionate early-day light and inadequate evening light favor phase advance. The effect depends on circadian timing, not simply total illumination.

Protective factors

No validated genetic protective allele has been established. Potential environmental countermeasures include adequate evening light, avoiding excessive early-morning light when a delay is desired, regular sleep timing, and aligning work/social obligations with the patient’s biological schedule. These are management principles rather than proven primary prevention.

Gene–environment interaction

Clock variants may change intrinsic period or the phase-resetting response to light. The 2023 genetics review emphasizes that implicated variants may be incompletely penetrant and their effects “masked by environmental factors”; controlled light and sleep schedules may therefore reveal phenotypes missed in ordinary conditions. (lane2023geneticsofcircadian pages 6-7)

3. Phenotypes

Symptoms must persist for at least 3 months, and objective records should demonstrate a stable advance. Severity varies from benign morning preference to clinically important evening sleepiness, insomnia, and schedule-related sleep restriction. Sleep itself is usually consolidated and normal when the patient follows the preferred schedule. (dodson2010therapeuticsforcircadian pages 4-5, sun2022treatmentofcircadian pages 5-6, auger2015clinicalpracticeguideline pages 9-10)

Frequency estimates for individual symptoms are unavailable; most literature consists of small families, clinic cohorts, or elderly samples. Disease-specific EQ-5D, SF-36, or PROMIS estimates were not identified.

4. Genetic and molecular information

The variant evidence is summarized below. “Established” here means replicated functional evidence in the source family/model, not necessarily a current ClinGen gene–disease validity classification.

Table: This table summarizes established and candidate familial advanced sleep phase genes and variants requested by the user, separating directly verified evidence from review-level or indirect support. It is useful for distinguishing high-confidence variant-mechanism pairs from associations that require primary-source confirmation.

Interpretation cautions

• PER2 p.Ser662Gly (S662G): germline missense variant in the CKIε-binding region; caused hypophosphorylation in vitro and segregated as a highly penetrant autosomal-dominant trait in the original family. (toh2001anhper2 pages 1-2)
• TIMELESS p.Arg1081Ter (R1081X): germline nonsense variant identified in a very small family; absent from public genome databases at the investigators’ 2018 cutoff. It causes protein instability and abnormal cytoplasmic retention rather than a conventional simple loss-of-function phenotype. (kurien2019timelessmutationalters pages 6-7, kurien2019timelessmutationalters pages 1-2)
• CSNK1D T44A, CRY2 A260T, and PER3 P415A/H417R: field-recognized FASP variants, but variant-level ClinVar classification, HGVS transcripts, and present-day gnomAD frequencies were not directly verified in the retrieved evidence. They should be curated from ClinVar/gnomAD against a specified transcript before knowledge-base ingestion.
• Somatic variants: not implicated; reported FASP variants are inherited germline variants.
• Chromosomal abnormalities, repeat expansions, mitochondrial variants, and large recurrent CNVs: no established role.
• Modifier genes/epigenetics: no validated modifier or disease-specific methylation signature is established.

The 2023 review warns that only limited families have been studied and recommends requiring variants in multiple unrelated affected individuals plus statistical segregation before confidently assigning a new gene. (lane2023geneticsofcircadian pages 6-7)

5. Environmental information

No toxin, infection, radiation exposure, pollution source, smoking pattern, diet, or occupational chemical exposure is known to cause Mendelian FASP. Light is the dominant environmental zeitgeber. Morning light tends to advance the clock, whereas appropriately timed evening light delays it. Shift work and transmeridian travel can mimic or obscure phase disorders; both were exclusion criteria in major observational protocols. (NCT00246454 chunk 1, NCT04690504 chunk 1)

Alcohol, caffeine, exercise, and irregular schedules can alter sleep expression but are not established primary causes. Infectious agents and zoonotic transmission are not applicable.

6. Mechanism and pathophysiology

Core causal chain

Clock-gene variant → altered phosphorylation/protein stability or light entrainment → abnormal PER/CRY negative feedback on CLOCK–BMAL1 → shortened or differently entrained circadian oscillation → early melatonin/temperature/sleep-propensity phase → evening sleepiness and early awakening → impairment when social time conflicts with biological time. (toh2001anhper2 pages 1-2, kurien2019timelessmutationalters pages 1-2)

In the canonical TTFL, CLOCK–BMAL1 activates circadian genes, including PER and CRY. PER/CRY complexes accumulate, enter the nucleus, and repress CLOCK–BMAL1. Their phosphorylation, turnover, and nuclear transport determine period and phase.

• PER2 S662G: impaired CKIε-dependent phosphorylation alters clock timing. (toh2001anhper2 pages 1-2)
• TIMELESS R1081X: prevents nuclear TIM accumulation, reduces CRY2 affinity, destabilizes the PER/CRY complex, and weakens repression of CLOCK–BMAL1. Unlike classic short-period variants, mutant mice show an advanced phase and abnormal photic entrainment with a normal organismal free-running period. (kurien2019timelessmutationalters pages 6-7, kurien2019timelessmutationalters pages 1-2)

Upstream versus downstream

• Upstream: germline clock variant and retinal light input.
• Intermediate: SCN TTFL kinetics, kinase activity, PER/CRY stability, and phase-response behavior.
• Downstream: advanced pineal melatonin secretion, body-temperature nadir, sleep propensity, endocrine/autonomic rhythms, and behavior.
• Clinical endpoint: mismatch between biological night and desired social schedule.

Cells, tissues, and ontology suggestions

• Primary cells: SCN circadian pacemaker neurons—suggest CL:0000540 neuron, with an SCN-specific extension; intrinsically photosensitive retinal ganglion cells (CL:0000740 retinal ganglion cell) provide photic input; pinealocytes produce melatonin.
• GO biological processes: circadian rhythm (GO:0007623), regulation of circadian rhythm (GO:0042752), entrainment of circadian clock by photoperiod (GO:0043153), protein phosphorylation (GO:0006468), transcriptional repression.
• GO cellular components: nucleus (GO:0005634), cytoplasm (GO:0005737), transcription regulator complex.

There is no established disease-specific immune activation, inflammation, tissue destruction, fibrosis, apoptosis, or metabolic-storage defect. Transcriptomic, proteomic, metabolomic, lipidomic, single-cell, and spatial signatures remain investigational rather than diagnostic.

7. Anatomical structures affected

ASWPD is primarily a functional nervous-system timing disorder, not a destructive lesion.

• Central pacemaker: suprachiasmatic nucleus of the anterior hypothalamus—suggest UBERON:0002034 hypothalamus, with SCN subdivision where supported.
• Input pathway: retina → retinohypothalamic tract → SCN; suggest UBERON:0000966 retina.
• Output: pineal gland/melatonin, autonomic and endocrine timing; suggest UBERON:0001905 pineal body.
• Subcellular compartments: nucleus and cytoplasm, particularly for PER/CRY/TIMELESS trafficking.
• Lateralization: none; circuitry is bilateral/systemic.

No structural MRI, histopathology, or biopsy abnormality is expected.

8. Temporal development

Onset is variable. Mendelian FASP can appear in childhood or early adulthood and often remains lifelong; age-associated advanced phase is predominantly later-life. Onset is generally chronic/insidious rather than acute. There are no formal stages or end-stage disease. Expression can fluctuate with season, light exposure, work schedule, retirement, and treatment adherence. (ashbrook2020geneticsofthe pages 4-5, lane2023geneticsofcircadian pages 6-7)

There is no established spontaneous remission rate. Phase delay achieved with light or scheduling may relapse after treatment stops because the underlying circadian tendency persists. Critical intervention windows are defined by circadian phase: mistimed light can shift the clock in the wrong direction.

9. Inheritance and population

Epidemiology

Estimates vary because advanced chronotype, early awakening in older adults, and diagnostically impaired ASWPD are often conflated.

• A 2023 genetics review reports ICSD-defined advanced SWPD prevalence up to 0.21%. (lane2023geneticsofcircadian pages 6-7)
• Another synthesis estimates at least 0.04% (1 in 2,500), based on approximately one in eight people with advanced sleep phase meeting disorder criteria. (ashbrook2020geneticsofthe pages 4-5)
• Reviews citing broader or older samples report 1–7%, and an elderly survey reported early waking in 20%; these figures should not be interpreted as genetically confirmed FASP prevalence. (sun2022treatmentofcircadian pages 5-6)
• Incidence per 100,000 person-years is unknown.

Inheritance

Familial cases usually show autosomal-dominant inheritance. The original PER2 family was described as highly penetrant, but penetrance across genes and families is not quantified and may be age- and environment-dependent. Expressivity is variable. Anticipation, germline mosaicism, consanguinity effects, carrier frequency, and reproducible founder effects have not been established. (lane2023geneticsofcircadian pages 6-7, toh2001anhper2 pages 1-2)

No robust ethnic, geographic, or sex-ratio estimates exist. Existing pedigrees are too small and ancestrally limited to support population-specific conclusions.

10. Diagnostics

Clinical criteria and workflow

1. Document a stable major sleep episode at least 2 hours earlier than required or desired.
2. Confirm evening sleepiness and/or early-morning or maintenance insomnia causing distress or functional impairment.
3. Confirm duration ≥3 months.
4. Establish that sleep quality and duration improve when the patient follows the naturally early schedule.
5. Record sleep diary plus wrist actigraphy for ≥7 days, preferably 14, including work and free days.
6. Exclude another sleep, medical, neurologic, psychiatric, medication-related, occupational, or environmental explanation. (sun2022treatmentofcircadian pages 5-6, auger2015clinicalpracticeguideline pages 9-10)

DLMO: serial salivary or plasma melatonin under dim light can document an advanced biological phase. A completed 2024 biomarker study defined salivary DLMO as the time melatonin rose above 3 pg/mL, with hourly samples beginning 7 hours before usual bedtime. (NCT04690504 chunk 1)

Actigraphy: useful for objective longitudinal timing; polysomnography is not routinely diagnostic but can exclude sleep apnea, periodic limb movements, or other sleep disorders.

Differential diagnosis

• Normal extreme morning chronotype without impairment.
• Age-related early sleep timing.
• Major depression with terminal insomnia—sleep is often nonrestorative and the entire circadian phase need not be advanced.
• Primary insomnia.
• Insufficient sleep syndrome.
• Obstructive sleep apnea, restless legs syndrome, periodic limb-movement disorder.
• Medication/substance effects.
• Shift-work disorder, jet lag, irregular sleep–wake rhythm disorder, and non-24-hour sleep–wake rhythm disorder.
• Dementia-related fragmented sleep and sundowning.

Genetic testing

Testing is most appropriate for a strongly familial, extreme, early-onset phenotype. A circadian-rhythm gene panel or exome/genome sequencing should include PER2, CSNK1D, CRY2, PER3, and TIMELESS, with cautious interpretation. Sequence and copy-number analysis is preferable to karyotyping or FISH. WES/WGS may identify novel variants, but segregation, population frequency, functional data, and ACMG/AMP classification are essential. CMA, mitochondrial sequencing, and repeat-expansion testing have no routine indication unless another phenotype suggests them.

Cascade testing is reasonable only after a pathogenic/likely pathogenic familial variant is established. Predictive testing of asymptomatic minors requires counseling because an early chronotype may not produce disease-level impairment.

Emerging diagnostics

The completed NCT04690504 study enrolled 50 adults and compared single-blood-sample proteomic and 15-transcript “body time” estimates with melatonin phase, demonstrating a current real-world attempt to make circadian phenotyping more accessible. Results establishing clinical validity were not available in the retrieved record. ClinicalTrials.gov NCT04690504, completed July 1, 2024. (NCT04690504 chunk 1)

11. Outcome and prognosis

ASWPD is not known to shorten life expectancy or directly increase mortality. Five- or ten-year survival statistics are therefore not applicable. Morbidity is primarily functional: evening sleepiness, curtailed social participation, occupational incompatibility, insomnia when resisting the preferred schedule, and secondary sleep deprivation. Normal sleep duration and quality are often restored when schedules are aligned with biological time. (ashbrook2020geneticsofthe pages 4-5, auger2015clinicalpracticeguideline pages 9-10)

Prognosis is generally good when schedule accommodation is feasible. Persistent genetic or age-related phase tendency means treatment often requires ongoing behavioral/light management. No validated molecular prognostic biomarker exists.

12. Treatment

Practical strategy

1. Confirm true circadian advance rather than insomnia or depression.
2. Where feasible, accommodate the naturally early schedule.
3. If phase delay is desired, use evening light, timed relative to DLMO/bedtime, and maintain a consistent delayed sleep–wake schedule.
4. Monitor symptoms and timing with diary/actigraphy; adjust to avoid paradoxical phase advance.
5. Treat comorbid insomnia, mood disorder, sleep apnea, or medication effects separately.

Evening light therapy

A clinical review recommends at least 5,000 lux for approximately 2 hours in the evening/night, but tolerance may be poor in older adults. (sun2022treatmentofcircadian pages 5-6)

The AASM guideline gives light therapy in adults with ASWPD a WEAK FOR recommendation with VERY LOW cumulative evidence. Its only identified randomized ASWPD trial included 47 participants, mean age 70.0 ± 6.4 years, and compared 28 days of broad-spectrum evening light (~265 lux for 2–3 hours, ending 1 hour before bedtime) with ~2-lux red light; no significant post-treatment group difference was found. (auger2015clinicalpracticeguideline pages 9-10)

Suggested ontology: NCIT:C15407 Phototherapy; light itself may be represented with an appropriate radiation/physical-agent term rather than CHEBI.

Scheduling and behavioral care

Prescribed sleep scheduling has only case-report support; one 62-year-old maintained desired times at 5-month follow-up after chronotherapy. AASM issued no recommendation because evidence was insufficient. Timed exercise and strategic light avoidance also received no recommendation. (auger2015clinicalpracticeguideline pages 9-10)

Sleep hygiene supports regularity but is not a stand-alone circadian treatment. CBT-I may help comorbid conditioned insomnia but does not correct the clock variant itself.

Melatonin and hypnotics

Evidence for melatonin in ASWPD is inadequate. In theory, carefully timed morning melatonin could delay circadian phase, but morning dosing may cause sleepiness and safety concerns; it is not supported by an AASM ASWPD recommendation. Evening melatonin would generally advance phase and may worsen ASWPD. (dodson2010therapeuticsforcircadian pages 4-5)

Hypnotics may suppress early-morning insomnia without correcting circadian phase. Disease-specific efficacy data are absent. Older adults face falls, confusion, amnesia, dependence, and next-day impairment; benzodiazepines and sedating antihistamines are particularly problematic. (auger2015clinicalpracticeguideline pages 9-10)

Suggested terms: NCIT:C101216 Melatonin where actually administered; melatonin is CHEBI:16796. There is no established pharmacogenomic guidance.

Advanced and experimental therapies

No approved gene therapy, CRISPR therapy, RNA therapy, cell therapy, surgery, immunotherapy, or disease-specific targeted drug exists. The current translational emphasis is on phase biomarkers and personalized timing rather than molecular correction.

Trials and implementations

• NCT00246454: completed observational Northwestern/NHLBI study of familial delayed and advanced sleep phase; 156 participants, 2003–March 27, 2024. Participants underwent questionnaires/actigraphy, with sleep measured over one night and circadian profiles over three days. ASPS inclusion required morning type and advanced melatonin onset. ClinicalTrials.gov. (NCT00246454 chunk 1)
• NCT04690504: completed prospective biomarker-validation study, 50 participants, comparing DLMO with transcriptomic/proteomic phase estimates. (NCT04690504 chunk 1)

No retrieved trial establishes a recent disease-specific drug response rate.

13. Prevention

Primary prevention of a germline FASP variant is not possible after conception. There is no vaccine, prophylactic medication, newborn screen, or population-screening program.

• Primary: maintain an appropriate light–dark schedule in genetically susceptible people; avoid chronic reinforcement of unwanted phase advance.
• Secondary: identify familial extreme morningness early when it causes school, work, or social impairment; use diary/actigraphy and targeted DLMO.
• Tertiary: prevent chronic sleep restriction, falls from sedating drugs, occupational impairment, and mood consequences by schedule accommodation and correctly timed light.
• Genetic counseling: explain autosomal-dominant transmission in established families, uncertain penetrance, variable impairment, and limitations of variant interpretation. Prenatal or preimplantation testing is technically possible after identification of a clearly pathogenic familial variant but is rarely proportionate for this generally manageable, non-lethal phenotype.

14. Other species and natural disease

No naturally occurring veterinary syndrome directly homologous to human FASP was established in the retrieved evidence. There is no zoonotic potential or cross-species transmission.

Circadian clock genes are strongly evolutionarily conserved. PER2, CRY proteins, casein kinase 1δ, and TIMELESS orthologues occur in mouse and other model species, enabling mechanistic comparison. Species-specific sleep architecture and light-response curves limit direct translation.

15. Model organisms

Mouse

The strongest newer model is the CRISPR TIMELESS R1081X knock-in mouse. It recapitulated advanced sleep–wake phase and altered sensitivity to light pulses while retaining a normal organismal period. CRISPR-mutant cells and mouse embryonic fibroblasts showed a shortened period, illustrating that cellular period and whole-animal behavior need not align perfectly. (kurien2019timelessmutationalters pages 6-7, kurien2019timelessmutationalters pages 1-2)

This model is useful for separating phase-response/entrainment defects from pure period shortening. Limitations include the small human source family, nocturnal mouse behavior, and species-specific light processing.

Cellular systems

HEK293T and U2OS cells, CRISPR-engineered cells, and mouse embryonic fibroblasts have been used to evaluate TIM localization, stability, CLOCK–BMAL1 repression, and PER/CRY destabilization. PER2 S662G was assessed by in-vitro phosphorylation assays. (kurien2019timelessmutationalters pages 6-7, toh2001anhper2 pages 1-2)

Invertebrates

Drosophila established the conserved conceptual framework for period and timeless genes, but mammalian TIMELESS is not functionally identical to Drosophila Tim. Human disease inference therefore requires mammalian validation. (kurien2019timelessmutationalters pages 1-2)

Recent developments and evidence gaps

The most authoritative recent synthesis, published in Nature Reviews Genetics in 2023, places ASWPD within a spectrum ranging from polygenic chronotype to rare Mendelian disease and emphasizes diverse-population sequencing, rigorous segregation, controlled phenotyping, and caution about incomplete penetrance. DOI: 10.1038/s41576-022-00519-z. (lane2023geneticsofcircadian pages 6-7)

The principal 2024 implementation development was completion of observational studies attempting to validate convenient transcriptomic/proteomic circadian-phase biomarkers and characterize familial phase disorders. These do not yet replace diary, actigraphy, or DLMO. (NCT00246454 chunk 1, NCT04690504 chunk 1)

Major gaps are: reliable incidence and population prevalence; ancestry-diverse pedigrees; ClinGen-level gene validity; quantified penetrance; prospective natural history; ASWPD-specific quality-of-life instruments; adequately powered, phase-marker-guided light trials; and controlled studies of combination treatment. The evidence base remains much smaller than for delayed sleep–wake phase disorder, so precise treatment claims should remain conservative.

References

1. (sun2022treatmentofcircadian pages 5-6): Shi-Yu Sun and Gui-Hai Chen. Treatment of circadian rhythm sleep–wake disorders. Jun 2022. URL: https://doi.org/10.2174/1570159x19666210907122933, doi:10.2174/1570159x19666210907122933. This article has 128 citations and is from a peer-reviewed journal.

2. (ashbrook2020geneticsofthe pages 4-5): Liza H. Ashbrook, Andrew D. Krystal, Ying-Hui Fu, and Louis J. Ptáček. Genetics of the human circadian clock and sleep homeostat. Neuropsychopharmacology, 45:45-54, Aug 2020. URL: https://doi.org/10.1038/s41386-019-0476-7, doi:10.1038/s41386-019-0476-7. This article has 182 citations and is from a highest quality peer-reviewed journal.

3. (auger2015clinicalpracticeguideline pages 9-10): R. Robert Auger, Helen J. Burgess, Jonathan S. Emens, Ludmila V. Deriy, Sherene M. Thomas, and Katherine M. Sharkey. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep-wake phase disorder (aswpd), delayed sleep-wake phase disorder (dswpd), non-24-hour sleep-wake rhythm disorder (n24swd), and irregular sleep-wake rhythm disorder (iswrd). an update for 20. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 11 10:1199-236, Oct 2015. URL: https://doi.org/10.5664/jcsm.5100, doi:10.5664/jcsm.5100. This article has 627 citations.

4. (lane2023geneticsofcircadian pages 6-7): Jacqueline M. Lane, Jingyi Qian, Emmanuel Mignot, Susan Redline, Frank A. J. L. Scheer, and Richa Saxena. Genetics of circadian rhythms and sleep in human health and disease. Nature Reviews Genetics, 24:4-20, Aug 2023. URL: https://doi.org/10.1038/s41576-022-00519-z, doi:10.1038/s41576-022-00519-z. This article has 289 citations and is from a domain leading peer-reviewed journal.

5. (kurien2019timelessmutationalters pages 1-2): Philip Kurien, Pei-Ken Hsu, Jacy Leon, David Wu, Thomas McMahon, Guangsen Shi, Ying Xu, Anna Lipzen, Len A. Pennacchio, Christopher R. Jones, Ying-Hui Fu, and Louis J. Ptáček. Timeless mutation alters phase responsiveness and causes advanced sleep phase. Proceedings of the National Academy of Sciences, 116:12045-12053, May 2019. URL: https://doi.org/10.1073/pnas.1819110116, doi:10.1073/pnas.1819110116. This article has 96 citations and is from a highest quality peer-reviewed journal.

6. (OpenTargets Search: advanced sleep phase syndrome): Open Targets Query (advanced sleep phase syndrome, 0 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

7. (NCT00246454 chunk 1): Phyllis Zee. Circadian Rhythms and Sleep in Familial DSPS and ASPS. Northwestern University. 2003. ClinicalTrials.gov Identifier: NCT00246454

8. (NCT04690504 chunk 1): Jeanne Duffy. Validation of Circadian Biomarkers in Patients With Sleep Disorders. Brigham and Women's Hospital. 2021. ClinicalTrials.gov Identifier: NCT04690504

9. (toh2001anhper2 pages 1-2): Kong L. Toh, Christopher R. Jones, Yan He, Erik J. Eide, William A. Hinz, David M. Virshup, Louis J. Ptáček, and Ying-Hui Fu. An h per2 phosphorylation site mutation in familial advanced sleep phase syndrome. Feb 2001. URL: https://doi.org/10.1126/science.1057499, doi:10.1126/science.1057499. This article has 1190 citations and is from a highest quality peer-reviewed journal.

10. (dodson2010therapeuticsforcircadian pages 4-5): Ehren R. Dodson and Phyllis C. Zee. Therapeutics for circadian rhythm sleep disorders. Sleep medicine clinics, 5 4:701-715, Dec 2010. URL: https://doi.org/10.1016/j.jsmc.2010.08.001, doi:10.1016/j.jsmc.2010.08.001. This article has 187 citations and is from a peer-reviewed journal.

11. (kurien2019timelessmutationalters pages 6-7): Philip Kurien, Pei-Ken Hsu, Jacy Leon, David Wu, Thomas McMahon, Guangsen Shi, Ying Xu, Anna Lipzen, Len A. Pennacchio, Christopher R. Jones, Ying-Hui Fu, and Louis J. Ptáček. Timeless mutation alters phase responsiveness and causes advanced sleep phase. Proceedings of the National Academy of Sciences, 116:12045-12053, May 2019. URL: https://doi.org/10.1073/pnas.1819110116, doi:10.1073/pnas.1819110116. This article has 96 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00